View in EDS HTML Full Text PDF Full Text

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Saved in:

Bibliographic Details
Title:	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Authors:	Sharmin, Sifat¹ (AUTHOR), Lefort, Mathilde^2,3 (AUTHOR), Andersen, Johanna Balslev⁴ (AUTHOR), Leray, Emmanuelle^2,3 (AUTHOR), Horakova, Dana⁵ (AUTHOR), Havrdova, Eva Kubala⁵ (AUTHOR), Alroughani, Raed⁶ (AUTHOR), Izquierdo, Guillermo⁷ (AUTHOR), Ozakbas, Serkan⁸ (AUTHOR), Patti, Francesco^9,10 (AUTHOR), Onofrj, Marco¹¹ (AUTHOR), Lugaresi, Alessandra^12,13 (AUTHOR), Terzi, Murat¹⁴ (AUTHOR), Grammond, Pierre¹⁵ (AUTHOR), Grand'Maison, Francois¹⁶ (AUTHOR), Yamout, Bassem¹⁷ (AUTHOR), Prat, Alexandre¹⁸ (AUTHOR), Girard, Marc¹⁸ (AUTHOR), Duquette, Pierre¹⁸ (AUTHOR), Boz, Cavit¹⁹ (AUTHOR)
Source:	CNS Drugs. Nov2021, Vol. 35 Issue 11, p1217-1232.
Database:	SPORTDiscus with Full Text
Full text is not displayed to guests. Login for full access.

Be the first to leave a comment!